TABLETING
to predict if material is going to produce strong or weak tablet. Tis system is the CDMCS described earlier (Fig. 2). If CM and DM of the material lies in
the green (Class-I) or light green colour (Class-II) region, then the material may result into robust tablets. If CM and DM of the material lies in the orange (Class-III) or red colour (Class-IV) region, then the material may result into poor tablets. High fragmenting materials will belong to Class-II and will form second strongest tablets after Class-I materials. Low fragmenting materials will fall into Class- III materials, and will form weaker tablets than Class-II materials. Predominately elastic materials will fall into Class-IV materials, which results in very weak tablets. Te materials that fall into Class-IV have high potential for tablet capping and lamination issues.
CONCLUSION Te present investigation proves that the proposed compression behaviour parameterisation methodology and classification system could serve as a ‘first-hand tool’ in an early formulation
Fig. 2. Compression-decompression modulus classification system (CDMCS)
development stage or as a ‘tableting problem diagnostic tool’ in the late development stage.
References [1] Sonnergaard JM. 1999. A critical evaluation of the Heckel equation. Int J Pharm. 193(1):63–71. https://doi. org/10.1016/S0378-5173(99)00319-1 [2] Patel DB, Patel VD, Haware R, Sedlock R. 2022. Negative porosity issue in the Heckel analysis: A possible solution. [place unknown].
[3] Choi DH, Kim NA, Rok CH, Jung JY, Yoon J-H, Jeong SH. 2010. Material properties and compressibility using Heckel and Kawakita equation with commonly used pharmaceutical excipients. J Pharm Investig. 40(4):237– 244.
https://doi.org/10.4333/kps.2010.40.4.237
Devang B. Patel, Vivek D. Patel, Robert Sedlock & Rahul V. Haware are with Natoli.
www.natoli.com
ONE TABLET PRESS, MANY DIFFERENT APPLICATIONS O
ral solid dosage forms play a significant role in the healthcare
industry today and will continue to do so in the future. According to the requirements of the pharmaceutical industry, modern tableting systems must be energy-efficient, flexible and multifunctional for processing increasingly powerful active pharmaceutical ingredients. GEA provided the answer at Achema 2022, where the machinery and equipment manufacturer and solution provider presented the new NexGen Press, a new tablet press product line. NexGen Press combines the advantages of GEA’s Modul and Performa rotary table press lines. The new line is not only a combination of existing technologies and available components, but a next-generation tablet press for the pharmaceutical industry. It is an advanced
solution for a wide range of tableting applications. “The NexGen Press is an example of our approach to digitalisation and modularisation,” explains Evelien Devroey at GEA Pharma & Healthcare. “By offering one machine with many applications, we are well prepared for the future. “Modular design means that a spectrum of containment capabilities (from basic protection to OEB 5. OEB 5 means a load of less than 1 µg/m3.) is available on a single
platform,” Devroey adds. Its maker believe it is also the first machine series compatible with both wash-offline (WOL) and wet-in-place (WIP) to meet a wide range of customer requirements. For example, the base model can be upgraded as needed to meet specific process requirements. Process requirements might include tableting two layers or different cleaning options
to further reduce the risk of cross- contamination. In addition, each machine is intuitive to
operate and benefits from a back-to-basics design philosophy. As with all GEA tablet presses, occupational and product safety, robust functionality, support and after-sales service come as standard.
For more information visit
www.gea.com
www.scientistlive.com 49
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60
